Some drugs that have gained approval this year so far include AstraZeneca’s Myalept (complications of leptin deficiency) and Farxiga (type II diabetes), Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) (to treat neurogenic orthostatic hypotension), BioMarin’s Vimizim (Morquio A syndrome) and Vanda Pharma’s Hetlioz. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) stock performance was -5.75% in last session and finished the day at $4.92. Traded volume was 3.02million shares in … Continue reading NASDAQ losers: Chelsea Therapeutics International (NASDAQ:CHTP), Pharmacyclics (NASDAQ:PCYC), ZIOPHARM Oncology (NASDAQ:ZIOP), Array Biopharma (NASDAQ:ARRY)